IQGAP1 and acute myeloid leukemia: In summary, the data presented show that a significant percentage of primary AML samples overexpress IQGAP1 and that a small molecule designed to target the GRD domain of IQGAP1 has the potential to inhibit AML with a favorable therapeutic index.